He was Faculty at McGill for six years before moving to Cambridge in 2011. Much of his research has focused on the Fanconi Anemia genes and hereditary breast cancer predisposition, but his interests cover all areas of hereditary cancer including the translation of recent advances in genome technology into clinical practice. He is the lead author on a New England Journal of Medicine article on breast cancer among PALB2 carriers and is considered a world-expert on PALB2. For further information on Dr. Tischkowitz, please click here. For more details about the PALB2 Interest Group, please click here.